Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 5/20 | 0.32 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15095354 | 0.93 | DGAT1 (0.31) | DGAT1CNR2 | |
| SCHEMBL12361968 | 0.82 | DGAT1 (0.39) | DGAT1CNR2RECQLNPSR1 | |
| SCHEMBL16656672 | 0.80 | CA1 (0.33) | CA1CA2 | |
| SCHEMBL20671829 | 0.78 | DGAT1 (0.37) | DGAT1CNR2NPSR1 | |
| SCHEMBL10013884 | 0.78 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL10042965 | 0.77 | ALDH1A1 (0.40) | NPSR1 | |
| SCHEMBL14902200 | 0.77 | MGAM (0.41) | DGAT1CNR2CA1CA2NPSR1 | |
| SCHEMBL484144 | 0.77 | CNR2 (0.36) | DGAT1CNR2NPSR1 | |
| SCHEMBL32683939 | 0.77 | MGAM (0.41) | DGAT1CNR2RECQLCA2NPSR1 | |
| SCHEMBL13596286 | 0.75 | MAPT (0.39) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481496-B2 | Gold (III) complexes with oligopeptides functionalized with sulfur donors and use thereof as antitumor agents | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2013-07-09 | — | — | US | disclosed |
| US-20120101044-A1 | GOLD (III) COMPLEXES WITH OLIGOPEPTIDES FUNCTIONALIZED WITH SULFUR DONORS AND USE THEREOF AS ANTITUMOR AGENTS | UNIVERSITA' DEGLI STUDI DI PADOVA | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101044-A1 | GOLD (III) COMPLEXES WITH OLIGOPEPTIDES FUNCTIONALIZED WITH SULFUR DONORS AND USE THEREOF AS ANTITUMOR AGENTS | UACA, UBXN4, PDIA3 | DGAT1 2930/4885CNR2 4856/4885RECQL 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.